| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BCGF1; Binetrakin; BSF1; IGG1 induction factor; IL4; Il4e12; ;IL 4 |
| WB Predicted band size | Calculated MW: 17 kDa ; Observed MW: 14 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IL 4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于IL-4抗体的代表性文献示例：
1. **"Dupilumab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis"**
- **作者**: Beck LA, et al.
- **摘要**: 该研究报道了抗IL-4受体α单克隆抗体Dupilumab的临床试验结果，证明其通过阻断IL-4和IL-13信号通路，显著改善中重度特应性皮炎患者的症状，且安全性良好。
2. **"IL-4 and IL-13 Signaling: From Discovery to Targeted Therapy for Allergic Diseases"**
- **作者**: Gandhi NA, et al.
- **摘要**: 综述了IL-4和IL-13在过敏性疾病中的作用机制，并讨论针对这些细胞因子的抗体药物(如Dupilumab)的研发进展及临床应用，强调其在哮喘和湿疹治疗中的突破性效果。
3. **"Structural Basis of IL-4 Receptor Signaling Modulation by Therapeutic Antibodies"**
- **作者**: LaPorte SL, et al.
- **摘要**: 通过X射线晶体学解析IL-4受体与不同治疗性抗体的复合物结构，揭示了抗体如何特异性结合并抑制IL-4/IL-13信号传导，为优化抗体药物设计提供理论依据。
4. **"Targeting IL-4 in Experimental Allergic Asthma Using Neutralizing Antibodies"**
- **作者**: Corren J, et al.
- **摘要**: 在小鼠模型中，使用抗IL-4中和抗体显著减少气道炎症和黏液分泌，表明IL-4在哮喘病理中的关键作用，为后续临床转化研究奠定基础。
(注：以上文献标题和内容为示例性概括，实际引用需以具体论文为准。)
**Background of IL-4 Antibodies**
Interleukin-4 (IL-4) is a pleiotropic cytokine produced primarily by activated T-helper 2 (Th2) cells, mast cells, and basophils. It plays a central role in regulating adaptive immunity by promoting Th2 differentiation, B-cell class switching to IgE/IgG4. and alternative activation of macrophages. IL-4 signals through the IL-4 receptor complex (IL-4Rα paired with either γc or IL-13Rα1), activating downstream pathways like JAK-STAT, which drive pro-inflammatory and anti-inflammatory responses depending on context. Dysregulated IL-4 signaling is implicated in allergic diseases (e.g., asthma, atopic dermatitis), fibrosis, and certain cancers.
IL-4 antibodies are therapeutic or research tools designed to neutralize IL-4 or block its receptor interactions. Monoclonal antibodies (mAbs) like dupilumab (anti-IL-4Rα) have been approved for treating Th2-driven conditions by inhibiting IL-4 and IL-13 signaling. These biologics reduce eosinophilic inflammation, IgE production, and tissue remodeling. Other investigational IL-4-targeting antibodies aim to modulate tumor microenvironments or autoimmune disorders by disrupting IL-4-mediated immune suppression or promoting anti-tumor immunity.
Despite their efficacy, challenges remain, including patient variability in response and potential side effects from broad immunosuppression. Ongoing research focuses on optimizing IL-4 antibody specificity, combination therapies, and biomarkers for personalized treatment in diverse IL-4-associated pathologies.
×
